MCID: PRT013
MIFTS: 59

Portal Hypertension

Categories: Rare diseases, Gastrointestinal diseases, Cardiovascular diseases

Aliases & Classifications for Portal Hypertension

MalaCards integrated aliases for Portal Hypertension:

Name: Portal Hypertension 12 72 49 28 14
Hypertension, Portal 49 41 69
Hypertension Portal 51

Classifications:



External Ids:

Disease Ontology 12 DOID:10762
ICD10 32 K76.6
ICD9CM 34 572.3
MeSH 41 D006975
NCIt 46 C3119
SNOMED-CT 64 155821005 34742003
UMLS 69 C0020541

Summaries for Portal Hypertension

NIH Rare Diseases : 49 Portal hypertensionis abnormally high blood pressure in branches of the portal vein, the large vein that brings blood from the intestine to the liver. Portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. It may be caused by a variety of conditions, but cirrhosis is the most common cause in Western countries. Treatment is generally directed toward the cause of the condition, although emergency treatment is sometimes needed for serious complications. Last updated: 2/1/2012

MalaCards based summary : Portal Hypertension, also known as hypertension, portal, is related to esophageal varix and hypersplenism, and has symptoms including signs and symptoms, digestive An important gene associated with Portal Hypertension is DGUOK (Deoxyguanosine Kinase), and among its related pathways/superpathways are Signaling by GPCR and PEDF Induced Signaling. The drugs Simvastatin and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 72 Portal hypertension is hypertension (high blood pressure) in the hepatic portal system – made up of the... more...

Related Diseases for Portal Hypertension

Diseases in the Portal Hypertension family:

Portal Hypertension Due to Infrahepatic Block

Diseases related to Portal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 349)
# Related Disease Score Top Affiliating Genes
1 esophageal varix 32.3 ALB F2 SST
2 hypersplenism 31.8 ALB F2 THPO
3 gastric antral vascular ectasia 30.9 CTC1 SST
4 thrombosis 30.5 F2 JAK2 VWF
5 hepatoportal sclerosis 30.5 F2 GPT
6 liver disease 30.3 ALB F2 GPT TNF
7 abdominal tuberculosis 30.3 ALB F2
8 schistosomiasis 30.2 ALB F2 TNF
9 alcoholic liver cirrhosis 30.0 ALB F2 TNF
10 hepatic coma 29.9 ALB F2 GPT
11 hepatorenal syndrome 29.9 ALB EDN1 F2
12 hepatitis b 29.8 ALB F2 GPT TNF
13 hepatic encephalopathy 29.8 ALB F2 GPT TNF
14 kidney disease 29.7 AGTR1 ALB EDN1 PKHD1
15 hepatic tuberculosis 29.7 ALB F2 GPT
16 cholelithiasis 29.7 ALB GPT SST
17 alcoholic hepatitis 29.7 ALB F2 GPT TNF
18 cholangitis 29.7 ALB F2 GPT TNF
19 peritonitis 29.7 ALB F2 TNF
20 choledocholithiasis 29.7 ALB F2 GPT
21 angiodysplasia 29.7 SST VEGFA VWF
22 acute liver failure 29.7 ALB F2 GPT
23 nonalcoholic steatohepatitis 29.6 F2 GPT TNF
24 viral hepatitis 29.3 ALB F2 GPT TNF
25 obstructive jaundice 29.3 ALB EDN1 F2 GPT TNF
26 hereditary hemorrhagic telangiectasia 29.2 BMPR2 NOS3 VEGFA VWF
27 liver cirrhosis 29.2 ALB EDN1 F2 GPT SST THPO
28 active peptic ulcer disease 28.9 F2 VWF
29 autosomal dominant polycystic kidney disease 28.9 ALB EDN1 EDNRA NOS3 PKHD1 VEGFA
30 hepatic vascular disease 28.7 ALB EDN1 F2 JAK2 NOS3 SST
31 hepatopulmonary syndrome 28.7 ALB EDN1 EDNRA NOS3 TNF VEGFA
32 vascular disease 28.5 BMPR2 EDN1 NOS3 VEGFA VWF
33 pulmonary hypertension 27.5 BMPR2 EDN1 EDNRA NOS3 UTS2 VEGFA
34 portal hypertension, noncirrhotic 12.5
35 colonic varices without portal hypertension 12.1
36 portal hypertension due to infrahepatic block 12.1
37 nodular regenerative hyperplasia 11.9
38 banti's syndrome 11.6
39 splenomegaly 11.3
40 congenital hepatic fibrosis 11.2
41 caroli disease 11.2
42 portal vein thrombosis 11.2
43 myelofibrosis 11.1
44 adams-oliver syndrome 1 11.1
45 polycystic kidney disease 4 with or without hepatic disease 10.9
46 budd-chiari syndrome 10.9
47 cerebroretinal microangiopathy with calcifications and cysts 1 10.9
48 cholangitis, primary sclerosing 10.9
49 cirrhosis, familial 10.7
50 coach syndrome 10.7

Comorbidity relations with Portal Hypertension via Phenotypic Disease Network (PDN): (show all 22)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Chronic Kidney Failure
Deficiency Anemia Esophageal Varix
Heart Disease Hepatic Encephalopathy
Hepatitis Hepatocellular Carcinoma
Hepatorenal Syndrome Hypersplenism
Iron Deficiency Anemia Neutropenia
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Urea Cycle Disorder

Graphical network of the top 20 diseases related to Portal Hypertension:



Diseases related to Portal Hypertension

Symptoms & Phenotypes for Portal Hypertension

UMLS symptoms related to Portal Hypertension:


signs and symptoms, digestive

MGI Mouse Phenotypes related to Portal Hypertension:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 VWF UTS2 VEGFA SST THPO TNF
2 growth/size/body region MP:0005378 10.29 TNF SST VEGFA EDNRA NOS3 F2
3 hematopoietic system MP:0005397 10.27 TNF VWF VEGFA THPO NOS3 F2
4 immune system MP:0005387 10.27 TNF VWF VEGFA SST THPO NOS3
5 cardiovascular system MP:0005385 10.26 TNF VWF VEGFA EDNRA NOS3 F2
6 cellular MP:0005384 10.25 VEGFA VWF TNF PKHD1 JAK2 EDNRA
7 mortality/aging MP:0010768 10.25 TNF VWF VEGFA SST NOS3 F2
8 digestive/alimentary MP:0005381 10.24 VWF VEGFA SST TNF NOS3 F2
9 endocrine/exocrine gland MP:0005379 10.18 TNF VEGFA EDNRA NOS3 PKHD1 JAK2
10 nervous system MP:0003631 10.06 TNF VWF SST VEGFA EDNRA NOS3
11 liver/biliary system MP:0005370 9.98 TNF UTS2 VEGFA NOS3 PKHD1 JAK2
12 normal MP:0002873 9.96 VEGFA SST NOS3 F2 PKHD1 JAK2
13 muscle MP:0005369 9.91 TNF VEGFA EDNRA NOS3 BMPR2 ALB
14 renal/urinary system MP:0005367 9.76 VEGFA NOS3 PKHD1 BMPR2 EDNRA AGTR1
15 respiratory system MP:0005388 9.5 TNF PKHD1 VEGFA EDNRA NOS3 F2
16 skeleton MP:0005390 9.32 TNF VEGFA SST NOS3 F2 GPT

Drugs & Therapeutics for Portal Hypertension

Drugs for Portal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
2
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
3
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
4
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
5
Nitric Oxide Approved Phase 4,Phase 3,Phase 2 10102-43-9 145068
6
Prazosin Approved Phase 4 19216-56-9 4893
7
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 525-66-6 4946
8
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
9
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
10 Racepinephrine Approved Phase 4,Phase 2 329-65-7
11
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
14
Dalteparin Approved Phase 4,Phase 3 9005-49-6
15
Dipyridamole Approved Phase 4 58-32-2 3108
16
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
17 Nadroparin Approved, Investigational Phase 4 9041-08-1
18
Warfarin Approved Phase 4,Phase 3 81-81-2 54678486 6691
19
Terlipressin Approved, Investigational Phase 4,Phase 3,Phase 2 14636-12-5 72081
20
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
21
Colchicine Approved Phase 4,Phase 2 64-86-8 2833 6167
22
Peginterferon alfa-2b Approved Phase 4,Phase 3 215647-85-1, 99210-65-8
23
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3 54-31-9 3440
24
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 83150-76-9 6400441 383414
25
Lactulose Approved Phase 4,Phase 2 4618-18-2 11333
26
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
27
Tranexamic Acid Approved Phase 4 1197-18-8 5526
28
Glucosamine Approved, Investigational, Nutraceutical Phase 4 3416-24-8 439213
29 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
30
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
31 Anticholesteremic Agents Phase 4,Phase 3,Phase 2
32 Antimetabolites Phase 4,Phase 3,Phase 2
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2
34 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
35 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
36 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Adrenergic Agents Phase 4,Phase 3,Phase 2
38 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
39 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2
40 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
41 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
42 Adrenergic alpha-Antagonists Phase 4,Phase 3
43 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
45 Autonomic Agents Phase 4,Phase 2,Phase 3
46 diuretics Phase 4,Phase 2,Phase 3
47 Isosorbide Phase 4
48 isosorbide-5-mononitrate Phase 4
49 Natriuretic Agents Phase 4,Phase 2,Phase 3
50 Nitric Oxide Donors Phase 4

Interventional clinical trials:

(show top 50) (show all 246)

# Name Status NCT ID Phase Drugs
1 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
2 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
3 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
4 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
5 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
6 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
7 Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
8 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
9 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
10 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
11 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
12 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
13 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
14 Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Completed NCT02994485 Phase 4 Simvastatin
15 Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
16 Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
17 Secondary Prophylaxis After Variceal Bleeding in Non-Responders Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
18 Short Course Terlipressin for Control of Acute Variceal Bleeding Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
19 Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis Completed NCT00570622 Phase 4 Pioglitazone;Placebo
20 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
21 Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
22 The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed Completed NCT00534677 Phase 4 Terlipressin;Octreotide
23 Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. Completed NCT00968695 Phase 4 Albumin
24 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Recruiting NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
25 Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis Recruiting NCT02907749 Phase 4 Spironolactone;Carvedilol
26 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4 Carvedilol
27 Preventing Recurrent Bleeding After Eradication of Esophageal Varices Recruiting NCT02740166 Phase 4 propranolol
28 Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Not yet recruiting NCT02945956 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu
29 Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Traditional Chinese Medicine and Entecavir Not yet recruiting NCT02945982 Phase 4 Entecavir+Carvedilol+ Placebo;Entecavir+Carvedilol+ Fuzheng Huayu;Entecavir+Carvedilol+ Fuzheng Huayu +TCM analysis
30 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Not yet recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
31 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
32 Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients Terminated NCT00188045 Phase 4 Propranolol - Spironolactone
33 Sodium Restriction in the Management of Cirrhotic Ascites Terminated NCT00548366 Phase 4
34 ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis Unknown status NCT01560845 Phase 2, Phase 3
35 Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
36 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
37 Probiotics for Portal Hypertension Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
38 Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
39 Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC Unknown status NCT02338297 Phase 3 EGM;PVA
40 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
41 ¹³C-Methacetin Breath Test (MBT) Methodology Study Unknown status NCT01205074 Phase 2, Phase 3 Non selective beta blocker - Propranolol
42 Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH) Completed NCT01000779 Phase 3 Propranolol
43 Simvastatin Effect on Portal Hypertension Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
44 Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Completed NCT01456286 Phase 2, Phase 3 sapropterin
45 Danish Carvedilol Study in Portal Hypertension Completed NCT00493480 Phase 3 carvedilol;propranolol
46 Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Completed NCT00331188 Phase 3 Sanvar® (vapreotide)
47 Prevention of Esophageal Varices by Beta-Adrenergic Blockers Completed NCT00006398 Phase 3 Timolol Maleate;Placebo
48 Comparing Two Methods to Stop Vomiting of Blood Using the Endoscope Completed NCT01131962 Phase 3
49 Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Completed NCT01654731 Phase 3 Bezafibrate;placebo
50 Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) Completed NCT00759109 Phase 3

Search NIH Clinical Center for Portal Hypertension

Cochrane evidence based reviews: hypertension, portal

Genetic Tests for Portal Hypertension

Genetic tests related to Portal Hypertension:

# Genetic test Affiliating Genes
1 Portal Hypertension 28

Anatomical Context for Portal Hypertension

MalaCards organs/tissues related to Portal Hypertension:

38
Liver, Spleen, Endothelial, Testes, Brain, Kidney, Bone

Publications for Portal Hypertension

Articles related to Portal Hypertension:

(show top 50) (show all 1048)
# Title Authors Year
1
Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis. ( 29429910 )
2018
2
Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. ( 29326427 )
2018
3
Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine? ( 29341272 )
2018
4
TMEM16A regulates portal vein smooth muscle cell proliferation in portal hypertension. ( 29434696 )
2018
5
Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine? Author's reply. ( 29341273 )
2018
6
Editorial: the portal hypertension puzzle-spleen stiffness evades validation as non-invasive marker of clinically significant portal hypertension. ( 29446131 )
2018
7
Ten-year experience of transjugular intrahepatic portosystemic shunt for noncirrhotic portal hypertension. ( 29324586 )
2018
8
Intentional Modulation of Portal Venous Pressure by Splenectomy Saves the Patient with Liver Failure and Portal Hypertension After Major Hepatectomy: Is Delayed Splenectomy an Acceptable Therapeutic Option for Secondary Portal Hypertension? ( 29410393 )
2018
9
Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. ( 29368385 )
2018
10
Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. ( 29391766 )
2018
11
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
12
Laparoscopic splenectomy and subsequent oncologic gastric surgery in cirrhotic patients with portal hypertension and hypersplenism. ( 29391322 )
2018
13
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. ( 29377193 )
2018
14
Letter: high oral dose of taurine for portal hypertension in cirrhotic patients-some clinical pharmacology considerations. ( 29446135 )
2018
15
Point Shear Wave Elastography of the Spleen: Its Role in Patients with Portal Hypertension. ( 29352618 )
2018
16
Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis. ( 29322599 )
2018
17
The "caput medusae" sign in portal hypertension. ( 29450607 )
2018
18
Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution. ( 29449343 )
2018
19
AlstrAPm Syndrome with Portal Hypertension. ( 29319259 )
2017
20
Spectrum of small-bowel mucosal abnormalities identified by capsule endoscopy in patients with portal hypertension of varied etiology. ( 28066855 )
2017
21
Outcomes of surgical shunts and transjugular intrahepatic portasystemic stent shunts for complicated portal hypertension. ( 28079252 )
2017
22
A Rare Cause of Portal Hypertension: Behcet's Disease and Nodular Regenerative Hyperplasia of the Liver. ( 28465872 )
2017
23
Laparoscopic distal splenoadrenal shunt for the treatment of portal hypertension in children with congenital hepatic fibrosis: A case report. ( 28099341 )
2017
24
Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension. ( 28836197 )
2017
25
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction. ( 27896916 )
2017
26
Combined caesarean with splenectomy in pregnancy with portal hypertension: defining plausibility. ( 28918404 )
2017
27
Portal hypertension and its management in children. ( 28814423 )
2017
28
Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results. ( 28918131 )
2017
29
Pseudo Symmer's Pipe-Stem Fibrosis in Idiopathic Noncirrhotic Portal Hypertension Associated with POEMS Syndrome. ( 28848769 )
2017
30
Management of Portal Hypertension After Liver Transplantation. ( 28838434 )
2017
31
Unsuccessful transjugular intrahepatic portosystemic shunt for a patient with right heart failure and portal hypertension. ( 29364100 )
2017
32
Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. ( 28824317 )
2017
33
Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis. ( 28822809 )
2017
34
Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. ( 27910154 )
2017
35
Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis. ( 28820885 )
2017
36
Non-invasive diagnosis of portal hypertension in cirrhosis using ultrasound based elastography. ( 28845498 )
2017
37
Comparison of physical parameter measurements between peripheral and portal blood samples in patients with portal hypertension. ( 28946596 )
2017
38
Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension. ( 28940597 )
2017
39
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension. ( 28855918 )
2017
40
Treatment of Refractory Gastrointestinal Bleeding in Patients With Portal Hypertension: A Case Series and Treatment Algorithm. ( 28923638 )
2017
41
Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis. ( 28478151 )
2017
42
Noninvasive assessment of portal hypertension and detection of esophageal varices in cirrhosis: state-of-the-art. ( 28079668 )
2017
43
Detailed EFSUM recommendations on the scope of ultrasound assessment in patients with portal hypertension considering the diagnostic reference level. ( 28856019 )
2017
44
Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. ( 26385087 )
2017
45
Non-cirrhotic portal hypertension in necrobiotic xanthogranuloma associated with monoclonal gammopathy. ( 28295661 )
2017
46
Portal hypertension as the initial manifestation of POEMS syndrome: a case report. ( 28503308 )
2017
47
Cholecystolithotomy Combined Armillarisin A versus Cholecystectomy in Cirrhotic Portal Hypertension Patients with Symptomatic Cholelithiasis. ( 28463673 )
2017
48
Elastography methods for the non-invasive assessment of portal hypertension. ( 28856972 )
2017
49
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. ( 27990835 )
2017
50
Current status of portal vein thrombosis in Japan: Results of a questionnaire survey by the Japan Society for Portal Hypertension. ( 28902450 )
2017

Variations for Portal Hypertension

Expression for Portal Hypertension

Search GEO for disease gene expression data for Portal Hypertension.

Pathways for Portal Hypertension

Pathways related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 AGTR1 BMPR2 EDN1 EDNRA F2 JAK2
2
Show member pathways
13.39 BMPR2 EDN1 EDNRA F2 JAK2 NOS3
3
Show member pathways
13.1 ALB F2 JAK2 NOS3 THPO VEGFA
4
Show member pathways
12.39 AGTR1 EDN1 F2 JAK2 NOS3 TNF
5
Show member pathways
12.3 AGTR1 F2 JAK2 NOS3 TNF
6 11.7 EDN1 NOS3 VEGFA
7
Show member pathways
11.68 F2 THPO VWF
8 11.5 BMPR2 EDN1 NOS3 TNF VEGFA
9 11.37 EDN1 NOS3 VEGFA
10 11.33 EDN1 EDNRA JAK2
11 11.1 AGTR1 EDN1 JAK2 NOS3 TNF VEGFA
12 11.03 EDN1 EDNRA NOS3
13
Show member pathways
10.91 EDN1 JAK2 VEGFA

GO Terms for Portal Hypertension

Cellular components related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 ALB EDN1 F2 SST THPO TNF
2 caveola GO:0005901 9.43 BMPR2 JAK2 NOS3
3 platelet alpha granule lumen GO:0031093 9.33 ALB VEGFA VWF
4 extracellular space GO:0005615 9.32 ALB BMPR2 EDN1 F2 GPT SST
5 Weibel-Palade body GO:0033093 8.96 EDN1 VWF

Biological processes related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 EDN1 F2 JAK2 PKHD1 VEGFA
2 regulation of cell proliferation GO:0042127 9.87 AGTR1 BMPR2 JAK2 TNF
3 in utero embryonic development GO:0001701 9.8 EDN1 EDNRA NOS3 VEGFA
4 positive regulation of DNA binding transcription factor activity GO:0051091 9.78 EDN1 JAK2 TNF
5 kidney development GO:0001822 9.77 AGTR1 PKHD1 VEGFA
6 regulation of inflammatory response GO:0050727 9.73 AGTR1 JAK2 TNF
7 positive regulation of MAP kinase activity GO:0043406 9.69 EDN1 TNF VEGFA
8 positive regulation of protein phosphorylation GO:0001934 9.67 F2 THPO TNF VEGFA
9 negative regulation of cAMP biosynthetic process GO:0030818 9.6 EDN1 EDNRA
10 regulation of blood vessel diameter GO:0097746 9.58 AGTR1 UTS2
11 positive regulation of endothelial cell migration GO:0010595 9.58 BMPR2 EDN1 VEGFA
12 positive regulation of cytosolic calcium ion concentration GO:0007204 9.56 AGTR1 EDN1 EDNRA JAK2
13 artery smooth muscle contraction GO:0014824 9.55 EDN1 EDNRA
14 negative regulation of platelet activation GO:0010544 9.54 F2 NOS3
15 endothelial cell apoptotic process GO:0072577 9.52 BMPR2 TNF
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.5 EDN1 JAK2 TNF
17 positive regulation of axon extension involved in axon guidance GO:0048842 9.46 BMPR2 VEGFA
18 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.43 EDN1 NOS3
19 branching involved in blood vessel morphogenesis GO:0001569 9.33 EDN1 EDNRA VEGFA
20 regulation of blood pressure GO:0008217 9.26 EDN1 EDNRA NOS3 UTS2
21 regulation of receptor activity GO:0010469 9.17 EDN1 F2 SST THPO TNF UTS2
22 G-protein coupled receptor signaling pathway GO:0007186 10.02 AGTR1 EDN1 EDNRA F2 JAK2 SST

Molecular functions related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 EDN1 THPO TNF VEGFA
2 hormone activity GO:0005179 8.92 EDN1 SST THPO UTS2

Sources for Portal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....